Former President and Chief Executive Officer · CRESCENT BIOPHARMA, INC. (CBIO)

Rachel King

A named executive officer of CRESCENT BIOPHARMA in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,420,848

Salary $511,146Stock awards $366,713

FY2020: $2,387,150

2nd of 4 named executive officers at Crescent Biopharma by FY2021 total.

4 named officers on file for CRESCENT BIOPHARMA, FY2021

Rachel King’s pay file — $29

  • 5 fiscal years of pay, line by line
  • CBIO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRESCENT BIOPHARMA’s whole pay program stands against its peers

  • CRESCENT BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Rachel King’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Rachel King compensation by year

CRESCENT BIOPHARMA Summary Compensation Table · all 5 fiscal years held
In US dollars, as CRESCENT BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021
Salary$502,500$543,000$559,300$576,079$511,146
Bonus$0$0$0$279,650$0
Stock awards$0$0$0$0$366,713
Option awards$747,250$2,350,250$1,844,400$1,190,090$520,955
Non-equity incentive$301,500$286,704$276,854$332,686$0
Pension and deferred compensation$0$0$0$0$0
All other$4,050$5,199$8,519$8,645$22,034
Total$1,555,300$3,185,153$2,689,073$2,387,150$1,420,848

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 11, 2022, accession 0001558370-22-005265, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CRESCENT BIOPHARMA, INC. filed document, accession 0001558370-22-005265. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2022.

$1.6M
$3.2M
$2.7M
$2.4M
$1.4M
FY17
FY18
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU96,250$138,600—
Option192,500—$3.81
Option181,770—$4.72
Option71,770—$10.59
Option3,645—$20.03

Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

7 Form 4 lines since the FY2021 proxy (filed April 11, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-05-01Grant or award derivative—40,000$0.0040,000
2024-03-29Grant or award—3,334$3.00515,194
2023-12-29Grant or award—4,238$2.36511,860
2023-09-30Grant or award—6,667$1.50507,622
2023-05-19Grant or award derivative—35,000$0.0035,000
2022-08-02W—7,500$0.007,500
2022-02-15W—11,641$0.00500,955

The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

CRESCENT BIOPHARMA’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Harout SemerjianPresident and Chief Executive Officer$2,876,118
Rachel King · this pageFormer President and Chief Executive Officer$1,420,848
Brian HahnSenior Vice President and Chief Financial Officer$1,122,561
John MagnaniSenior Vice President of Research and Chief Scientific Officer$1,121,337

Board service

CRESCENT BIOPHARMA board · FY2021–FY2023
Director compensation in US dollars, as CRESCENT BIOPHARMA reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2023$40,000—$56,000—$96,000
FY2022$40,000—$9,240$186,433$235,673
FY2021$0$0$0——

Each year as the company reported it in CRESCENT BIOPHARMA's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: CRESCENT BIOPHARMA pays directors a $40,000 cash retainer. As stated in CRESCENT BIOPHARMA's FY2023 proxy.

The full CRESCENT BIOPHARMA compensation record

free company brief

This page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rachel King's compensation dossier · One-time report. No refunds.